Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Open-label Study to Assess the Safety and Tolerability of Nebulized PC945 for Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

NCT05037851 is registered in ClinicalTrials.gov with Pulmocide Ltd as lead sponsor.

NCT NCT05037851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05037851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Open-label Study to Assess the Safety and Tolerability of Nebulized PC945 for Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
Lead sponsor
Pulmocide Ltd
Phase
Phase 2
Overall status
Completed
Start date
November 19, 2021
Completion date
November 13, 2023
Enrollment
102 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary aspergillosis